Wellington Management Group LLP Reduces Stake in Humana Inc. (NYSE:HUM)

Wellington Management Group LLP lessened its position in shares of Humana Inc. (NYSE:HUM) by 44.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 2,570,439 shares of the insurance provider’s stock after selling 2,020,721 shares during the quarter. Wellington Management Group LLP owned 2.13% of Humana worth $652,146,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of the company. Brandywine Global Investment Management LLC purchased a new stake in shares of Humana during the 4th quarter valued at about $51,105,000. Allianz SE purchased a new stake in Humana during the fourth quarter valued at approximately $3,549,000. Allstate Corp bought a new position in Humana in the fourth quarter worth approximately $905,000. Orion Portfolio Solutions LLC boosted its stake in shares of Humana by 3.7% during the 4th quarter. Orion Portfolio Solutions LLC now owns 4,834 shares of the insurance provider’s stock worth $1,226,000 after acquiring an additional 171 shares during the last quarter. Finally, denkapparat Operations GmbH bought a new stake in shares of Humana during the 4th quarter valued at $323,000. Institutional investors own 92.38% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages recently commented on HUM. Barclays raised their target price on Humana from $255.00 to $270.00 and gave the stock an “equal weight” rating in a report on Thursday, February 13th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $283.00 price objective on shares of Humana in a research report on Wednesday, February 12th. Piper Sandler boosted their price objective on Humana from $270.00 to $288.00 and gave the company a “neutral” rating in a research note on Wednesday, January 15th. Truist Financial raised their target price on shares of Humana from $260.00 to $290.00 and gave the stock a “hold” rating in a research note on Monday, January 6th. Finally, StockNews.com lowered shares of Humana from a “buy” rating to a “hold” rating in a research report on Tuesday, March 18th. Eighteen investment analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $285.68.

Humana Stock Down 0.1 %

Shares of HUM opened at $264.35 on Tuesday. The business’s 50 day simple moving average is $269.77 and its 200-day simple moving average is $273.07. Humana Inc. has a 1 year low of $213.31 and a 1 year high of $406.46. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.76 and a quick ratio of 1.76. The stock has a market capitalization of $31.91 billion, a price-to-earnings ratio of 26.57, a price-to-earnings-growth ratio of 2.05 and a beta of 0.57.

Humana (NYSE:HUM) last released its quarterly earnings data on Tuesday, February 11th. The insurance provider reported ($2.16) EPS for the quarter, beating the consensus estimate of ($2.26) by $0.10. Humana had a net margin of 1.02% and a return on equity of 11.70%. As a group, equities analysts expect that Humana Inc. will post 16.47 earnings per share for the current fiscal year.

Humana Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, April 25th. Shareholders of record on Friday, March 28th will be given a dividend of $0.885 per share. The ex-dividend date is Friday, March 28th. This represents a $3.54 dividend on an annualized basis and a yield of 1.34%. Humana’s dividend payout ratio (DPR) is presently 35.58%.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.